These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32624244)

  • 1. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
    Jaffe GJ; Pavesio CE;
    Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
    Jaffe GJ; Foster CS; Pavesio CE; Paggiarino DA; Riedel GE
    Ophthalmology; 2019 Apr; 126(4):601-610. PubMed ID: 30367884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.
    Biswas J; Tyagi M; Agarwal M;
    Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
    Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
    Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis.
    Pavesio C; Heinz C
    Eye (Lond); 2022 Jun; 36(6):1231-1237. PubMed ID: 34117380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
    Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
    JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
    Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.
    Buhl L; Thurau S; Kern C
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
    Malone PE; Herndon LW; Muir KW; Jaffe GJ
    Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
    Chieh JJ; Carlson AN; Jaffe GJ
    Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Results of 0.19mg Fluocinolone Acetonide Insert for Treatment of Non-Infectious Uveitis in Clinical Practice.
    Buhl L; Schmelter V; Schworm B; Thurau S; Kern C
    Ocul Immunol Inflamm; 2024 Sep; 32(7):1395-1399. PubMed ID: 37656834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Institution Experience of Intravitreal 0.18-mg Fluocinolone Acetonide Implant for Noninfectious Uveitis.
    Reddy AK; Pecen PE; Patnaik JL; Palestine AG
    Ophthalmol Retina; 2023 Jan; 7(1):67-71. PubMed ID: 35820567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IOP Elevation in Patients Treated With Fluocinolone Acetonide Insert for Chronic Noninfectious Uveitis Affecting the Posterior Segment.
    Singer MA; Krambeer C; Paggiarino D
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jul; 52(7):387-390. PubMed ID: 34309426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluocinolone acetonide intravitreal implant (Retisert
    Leinonen S; Immonen I; Kotaniemi K
    Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.